IRGQ1 Inhibitors
IRGQ1 Inhibitors are a class of chemical compounds that indirectly influence the functional activity of IRGQ1 by targeting specific signaling pathways or molecules involved in its regulation. Wortmannin and LY294002, as PI3K inhibitors, lead to the downregulation of AKT activity, which in turn is crucial for the function of IRGQ1 in survival pathways. The inhibition of PI3K and subsequent reduction in AKT phosphorylation by these compounds result in decreased functional activity of IRGQ1. Rapamycin and Everolimus, both mTOR inhibitors, disrupt downstream signaling that is essential for cellular processes such as growth and proliferation; processes in which IRGQ1 is implicated. The attenuation of mTOR activity by these compounds leads to a decrease in the functional activity of IRGQ1.
Src kinase inhibitor PP2 prevents phosphorylation of substrates that are key to survival and proliferation signaling, potentially reducing the activation and function of IRGQ1. PD173074, an FGFR inhibitor, impedes the activity of fibroblast growth factor receptors that may be upstream regulators of IRGQ1, leading to its decreased activity. U0126 and SB203580 target the MAPK/ERK and p38 MAPK pathways, respectively, both of which are integral to cell cycle progression and stress responses. Inhibition of these kinases by U0126 and SB203580 is likely to reduce IRGQ1 activity, as IRGQ1 is modulated by these pathways. SP600125, a JNK inhibitor, impacts stress response signaling that may regulate IRGQ1, effectively reducing its activity. Dasatinib and Sorafenib, by inhibiting BCR-ABL, Src family kinases, RAF kinase, VEGFR, and PDGFR, impact signaling networks that converge on mechanisms controlling IRGQ1 function. Sunitinib, with its multi-targeted approach, also suppresses various receptor tyrosine kinases, leading to diminished IRGQ1 activity by affecting the signaling pathways that regulate its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor that prevents phosphorylation of AKT, a kinase involved in survival pathways. Since IRGQ1 is downstream of AKT signaling, inhibition of PI3K by Wortmannin would reduce AKT activity, leading to reduced activity of IRGQ1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor, LY294002 diminishes AKT phosphorylation. As AKT can directly influence the function of IRGQ1, its inhibition by LY294002 leads to decreased IRGQ1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that impairs downstream signaling required for cell growth and proliferation. IRGQ1, being associated with such processes, would have reduced functional activity due to mTOR inhibition by Rapamycin. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src kinase inhibitor that prevents phosphorylation of substrates involved in cell survival and proliferation. By inhibiting Src kinases, PP2 can decrease the phosphorylation and activation of IRGQ1. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
FGFR inhibitor known to block the fibroblast growth factor receptor's activity. Since IRGQ1 may function downstream of FGFR in certain signaling pathways, PD173074 indirectly leads to decreased IRGQ1 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor that blocks the MAPK/ERK pathway, a key regulatory pathway for cell cycle progression. By inhibiting MEK, U0126 would lead to decreased activation of IRGQ1, which is influenced by the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor known for its role in inflammatory responses and apoptosis. Inhibition of p38 MAPK by SB203580 would lead to a decrease in IRGQ1 activity, which is modulated by stress-activated pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that impedes the JNK signaling involved in stress responses. By inhibiting JNK, SP600125 would lead to decreased functional activity of IRGQ1, which can be regulated by stress-activated signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
BCR-ABL and Src family kinase inhibitor. By inhibiting these kinases, Dasatinib can indirectly decrease IRGQ1 activity, which may be modulated by signaling pathways involving Src kinases. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAF kinase inhibitor that also inhibits VEGFR and PDGFR. As these pathways can converge on signaling events that modulate IRGQ1, Sorafenib can indirectly lead to decreased IRGQ1 activity. | ||||||